Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Olmesartan Medoxomil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 13/20 | 0.99 |
| ▸ | AGTR2 | P50052 | 12/20 | 0.99 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.99 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.99 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.99 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.99 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.99 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.99 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.99 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.99 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.99 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Olmesartan Medoxomil SCHEMBL29087653 | 0.99 | AGTR1 (1.00) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| Olmesartan Medoxomil SCHEMBL28341316 | 0.99 | AGTR1 (1.00) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| Olmesartan Medoxomil SCHEMBL16403 | 0.99 | AGTR1 (1.00) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| Olmesartan Medoxomil SCHEMBL27934840 | 0.99 | AGTR1 (0.99) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| Olmesartan Medoxomil SCHEMBL27822335 | 0.99 | AGTR1 (0.99) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| Olmesartan Medoxomil SCHEMBL28754180 | 0.99 | AGTR1 (0.99) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| Olmesartan Medoxomil SCHEMBL28547990 | 0.99 | AGTR1 (0.99) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| Olmesartan Medoxomil SCHEMBL28754188 | 0.98 | AGTR1 (0.97) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| Olmesartan Medoxomil SCHEMBL28754174 | 0.98 | AGTR1 (0.97) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| Olmesartan Medoxomil SCHEMBL29067178 | 0.97 | AGTR1 (0.95) | AGTR1AGTR2ABCC3ABCC4ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10149909-B2 | Fortifier | TORAY INDUSTRIES, INC. (JP) | 2018-12-11 | — | — | US | disclosed |
| EP-1627638-B1 | BERAPROST AND A RENIN-ANGIOTENSIN SYSTEM INHIBITOR FOR USE IN THE TREATMENT OF RENAL DISEASES | TORAY INDUSTRIES (JP) | 2017-07-12 | — | — | EP | disclosed |
| US-20170080089-A1 | FORTIFIER | TORAY INDUSTRIES, INC. (JP) | 2017-03-23 | — | — | US | disclosed |
| US-9546145-B2 | Combination therapy for the treatment of chronic renal failure with an angiotensin II receptor antagonist and beraprost | TORAY INDUSTRIES, INC. (JP) | 2017-01-17 | — | — | US | disclosed |
| CN-101439039-B | Fortifier | TORAY INDUSTRIES | 2012-06-13 | — | — | CN | disclosed |
| US-20090176848-A1 | FORTIFIER | TORAY INDUSTRIES, INC., A CORPORATION OF JAPAN (JP) | 2009-07-09 | — | — | US | disclosed |
| CN-101439039-A | Fortifier | TORAY INDUSTRIES (JP) | 2009-05-27 | — | — | CN | disclosed |
| CN-100477995-C | Fortifier | TORAY INDUSTRIES (JP) | 2009-04-15 | — | — | CN | disclosed |
| US-20060217421-A1 | Fortifier | TORAY INDUSTRIES, INC. (JP) | 2006-09-28 | — | — | US | disclosed |
| CN-1784235-A | Fortifier | TORAY INDUSTRIES (JP) | 2006-06-07 | — | — | CN | disclosed |
| EP-1627638-A1 | FORTIFIER | TORAY INDUSTRIES, INC. (JP) | 2006-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176848-A1 | FORTIFIER | REN, ACE, PTGER1 | AGTR1 10/4885AGTR2 39/4885ABCC3 3932/4885 |
| US-10149909-B2 | Fortifier | REN, ACE, AGT | AGTR1 7/4885AGTR2 17/4885ABCC3 3628/4885 |
| US-20170080089-A1 | FORTIFIER | REN, ACE, AGT | AGTR1 7/4885AGTR2 17/4885ABCC3 3628/4885 |
| US-20060217421-A1 | Fortifier | REN, PTGER1, GPR132 | AGTR1 8/4885AGTR2 22/4885ABCC3 3693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.